Dolutegravir or lower-dose efavirenz equally effective, but less resistance with dolutegravir
Dolutegravir-based treatment was no more effective than treatment based on a 400mg dose of efavirenz, a randomised trial conducted in Cameroon has found. However, almost half of people with very high viral loads taking either regimen had a detectable viral load after 48 weeks, the HIV Glasgow 2018 conference heard. Despite the non-inferiority of efavirenz-based… Read More »